20
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Call for Papers: Green Renal Replacement Therapy: Caring for the Environment

      Submit here before July 31, 2024

      About Blood Purification: 3.0 Impact Factor I 5.6 CiteScore I 0.83 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Nephritogenic Glycoprotein. XII. Focal Glomerulonephritis with Myeloid Bodies Produced in Rats by Synthetic Analogues of the Glycopeptide, Nephritogenoside

      research-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Glomerular lesions were successfully induced in rats by a single footpad injection of synthetic analogues of nephritogenoside [α-Glc-(1→6)-β-Glc-(1→6)-α-Glc-(1-NHCO-Asn, and -Gln)]. Characteristic morphological changes of these glomerular lesions are (1) focal glomerulonephritis (FGN) and (2) the appearance of myeloid bodies in the epithelial cells of the podocytes. FGN produced by a single injection of the synthetic analogues of nephritogenoside may provide an experimental animal model of this potentially diffuse disease, since morphological changes in the early stage of sclerosing glomerulonephritis (end-stage kidney) induced by a single footpad injection of natural nephritogenoside are often identical to those of FGN.

          Related collections

          Author and article information

          Journal
          NEF
          Nephron
          10.1159/issn.1660-8151
          Nephron
          S. Karger AG
          1660-8151
          2235-3186
          1987
          1987
          05 December 2008
          : 47
          : 2
          : 101-108
          Affiliations
          Clinical Research Institute, National Medical Center, Tokyo, Japan
          Article
          184469 Nephron 1987;47:101–108
          10.1159/000184469
          2827042
          e3b43eb5-74ac-46f9-87b6-4a933dacd72a
          © 1987 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          : 16 January 1987
          Page count
          Pages: 8
          Categories
          Original Paper

          Cardiovascular Medicine,Nephrology
          IgA nephropathy,Storage disease,Trihexosyl ceramide,Aminoglycoside antibiotics,Diffuse chronic glomerulonephritis,Immunofluorescent mesangial pattern

          Comments

          Comment on this article